Of Hong Kong and WEX Pharmaceuticals Inc.

The 116,852,062 extra restricted voting shares getting acquired by CKLS represent 66.02 percent of the restricted voting shares outstanding following the conversion. Mr. Alan Yu, Vice-President and Chief Working Officer of CKLS and Chairman of the Table of WEX stated: ‘CKLS has determined that it is appropriate to exercise its conversion right at this juncture under the conditions of the Convertible Debenture. The acquisition of this additional equity stake has been produced as a strategic purchase.’ CKLS may later on increase or decrease its possession in securities of WEX according to the business and potential customers of WEX and/or CKLS as well as market conditions..Related StoriesFDA grants accelerated acceptance for Tagrisso to treat patients with advanced NSCLCMD Anderson research reveals why chemotherapy medicines not effective for many pancreatic cancer patientsNew results reveal association between colorectal cancer and melanoma drug treatmentCharles M. Perou, Ph.D., associate professor of genetics and pathology at the Lineberger Cancer Middle at the University of North Carolina, will receive the 2009 AACR Excellent Investigator Award for Breast Cancer Research, which can be funded by Susan G. Komen for the Treatment. Perou’s lab focuses on genetic technology and its application to breast cancer. He primarily demonstrated that breast cancers can be divided into five unique molecular subtypes and that those subtypes could be applied to certain demographic populations to predict risk.